Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Randomized Trial of Second Line Treatment for Corticosteroid-Resistant or Relapsed Immune Thrombocytopenia: Combined Terbutaline and Danazol Versus Danazol Monotherapy

NCT05494307 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT05494307
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05494307 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Randomized Trial of Second Line Treatment for Corticosteroid-Resistant or Relapsed Immune Thrombocytopenia: Combined Terbutaline and Danazol Versus Danazol Monotherapy
Lead sponsor
Peking University People's Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
September 1, 2022
Completion date
February 28, 2024
Enrollment
228 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenia